Quakkelaar, Esther D. Redeker, Anke Haddad, Elias K. Harari, Alexandre McCaughey, Stella Mayo Duhen, Thomas Filali-Mouhim, Abdelali Goulet, Jean-Philippe Loof, Nikki M. Ossendorp, Ferry Perdiguero, Beatriz Heinen, Paul Gomez, Carmen E. Kibler, Karen V. Koelle, David M. Sékaly, Rafick P. Sallusto, Federica Lanzavecchia, Antonio Pantaleo, Giuseppe Esteban, Mariano Tartaglia, Jim Jacobs, Bertram L. Melief, Cornelis J. M. 2011-02-15 Attenuated poxviruses are safe and capable of expressing foreign antigens. Poxviruses are applied in veterinary vaccination and explored as candidate vaccines for humans. However, poxviruses express multiple genes encoding proteins that interfere with components of the innate and adaptive immune response. This manuscript describes two strategies aimed to improve the immunogenicity of the highly attenuated, host-range restricted poxvirus NYVAC: deletion of the viral gene encoding type-I interferon-binding protein and development of attenuated replication-competent NYVAC. We evaluated these newly generated NYVAC mutants, encoding HIV-1 env, gag, pol and nef, for their ability to stimulate HIV-specific CD8 T-cell responses in vitro from blood mononuclear cells of HIV-infected subjects. The new vectors were evaluated and compared to the parental NYVAC vector in dendritic cells (DCs), RNA expression arrays, HIV gag expression and crosspresentation assays in vitro. Deletion of type-I interferon-binding protein enhanced expression of interferon and interferoninduced genes in DCs, and increased maturation of infected DCs. Restoration of replication competence induced activationof pathways involving antigen processing and presentation. Also, replication-competent NYVAC showed increased Gag expression in infected cells, permitting enhanced cross-presentation to HIV-specific CD8 T cells and proliferation of HIVspecific memory CD8 T-cells in vitro. The recombinant NYVAC combining both modifications induced interferon-induced genes and genes involved in antigen processing and presentation, as well as increased Gag expression. This combined replication-competent NYVAC is a promising candidate for the next generation of HIV vaccines. application/pdf https://n2t.net/ark:/12658/srd1318987 https://susi.usi.ch/global/documents/318987 https://susi.usi.ch/documents/318987/files/quakkelaar_pone_2011.pdf eng info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0016819 info:eu-repo/semantics/altIdentifier/ark/12658/srd1318987 info:eu-repo/semantics/openAccess CC BY Plos one. - 2011, vol. 6, no. 2, p. e16819 info:eu-repo/classification/udc/61 Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors http://purl.org/coar/resource_type/c_6501